Aurora Cannabis Inc. ACB, +1.10% ACB, +0.80% filed for a potential sale of $300 million in fresh shares Thursday, and mentioned the possibility of a U.S. acquisition. The Canadian cannabis company announced that it planned a $300 million at-the-market share offering while releasing quarterly earnings last week, and filed a prospectus with the Securities and Exchange Commission for the sale on Thursday. In both the prospectus and a news release announcing the filing, Aurora suggested the proceeds would be used toward finding an acquisition target in the U.S. market. “Aurora believes this filing will provide maximum flexibility for the Company to pursue select acquisitions going forward, including within the U.S.,” the company stated in its release. “Aurora confirms that its current cash position remains strong at approximately $525 million as of May 13, 2021. Given the strength of Aurora’s current cash position, it is not expected to need to access the ATM Program without an accretive use of proceeds.” Aurora agreed to purchase a U.S. CBD company last year, but could be looking for a more traditional marijuana asset in the U.S. as many of the country’s states legalize recreational sales of the drug. Canadian companies are not allowed to own cannabis companies in the U.S., as the drug is still federally illegal in the country, but can acquire warrants to own a company if or when the drug is decriminalized federally. Aurora’s U.S.-listed stock was about 1.5% higher heading into the close Thursday, after falling nearly 40% in the past three months.
View Article Origin Here
